155 related articles for article (PubMed ID: 35018451)
1. Inflammatory Bowel Disease Risk Variants Are Associated with an Increased Risk of Skin Cancer.
Cushing KC; Du X; Chen Y; Stetson LC; Kuppa A; Chen VL; Kahlenberg JM; Gudjonsson JE; Vanderwerff B; Higgins PDR; Speliotes EK
Inflamm Bowel Dis; 2022 Nov; 28(11):1667-1676. PubMed ID: 35018451
[TBL] [Abstract][Full Text] [Related]
2. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease.
Long MD; Martin CF; Pipkin CA; Herfarth HH; Sandler RS; Kappelman MD
Gastroenterology; 2012 Aug; 143(2):390-399.e1. PubMed ID: 22584081
[TBL] [Abstract][Full Text] [Related]
3. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease.
Long MD; Herfarth HH; Pipkin CA; Porter CQ; Sandler RS; Kappelman MD
Clin Gastroenterol Hepatol; 2010 Mar; 8(3):268-74. PubMed ID: 20005977
[TBL] [Abstract][Full Text] [Related]
4. The presence of genetic risk variants within PTPN2 and PTPN22 is associated with intestinal microbiota alterations in Swiss IBD cohort patients.
Yilmaz B; Spalinger MR; Biedermann L; Franc Y; Fournier N; Rossel JB; Juillerat P; Rogler G; Macpherson AJ; Scharl M
PLoS One; 2018; 13(7):e0199664. PubMed ID: 29965986
[TBL] [Abstract][Full Text] [Related]
5. The risk of non-melanoma skin cancer in New Zealand in inflammatory bowel disease patients treated with thiopurines.
Bahi M; Walmsley RS; Gray AR; Young D; Hobbs CE; Aluzaite K; Schultz M
J Gastroenterol Hepatol; 2018 May; 33(5):1047-1052. PubMed ID: 29105142
[TBL] [Abstract][Full Text] [Related]
6. The PTPN22 C1858T (R620W) functional polymorphism in inflammatory bowel disease.
Zaid Y; Senhaji N; Bakhtaoui FZ; Serrano A; Serbati N; Karkouri M; Badre W; Oudghiri M; Martin J; Nadifi S
BMC Res Notes; 2018 Nov; 11(1):783. PubMed ID: 30384859
[TBL] [Abstract][Full Text] [Related]
7. Nonmelanoma Skin Cancer Risk in Patients With Inflammatory Bowel Disease Undergoing Thiopurine Therapy: A Systematic Review of the Literature.
Hagen JW; Pugliano-Mauro MA
Dermatol Surg; 2018 Apr; 44(4):469-480. PubMed ID: 29315147
[TBL] [Abstract][Full Text] [Related]
8. Risks of Melanoma and Nonmelanoma Skin Cancers Pre- and Post-Inflammatory Bowel Disease Diagnosis.
Narous M; Nugent Z; Singh H; Bernstein CN
Inflamm Bowel Dis; 2023 Jul; 29(7):1047-1056. PubMed ID: 35929649
[TBL] [Abstract][Full Text] [Related]
9. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System.
McKenna MR; Stobaugh DJ; Deepak P
J Gastrointestin Liver Dis; 2014 Sep; 23(3):267-71. PubMed ID: 25267954
[TBL] [Abstract][Full Text] [Related]
10. A More Severe Non-melanoma Skin Cancer Phenotype Is Seen in Patients with Inflammatory Bowel Disease on Tumor Necrosis Factor-α Antagonists.
Townsend CM; Khanna R; Wilson AS
Dig Dis Sci; 2021 Dec; 66(12):4436-4440. PubMed ID: 33428042
[TBL] [Abstract][Full Text] [Related]
11. Risk of skin cancers in thiopurines-treated and thiopurines-untreated patients with inflammatory bowel disease: A systematic review and meta-analysis.
Huang SZ; Liu ZC; Liao WX; Wei JX; Huang XW; Yang C; Xia YH; Li L; Ye C; Dai SX
J Gastroenterol Hepatol; 2019 Mar; 34(3):507-516. PubMed ID: 30393891
[TBL] [Abstract][Full Text] [Related]
12. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease.
Singh H; Nugent Z; Demers AA; Bernstein CN
Gastroenterology; 2011 Nov; 141(5):1612-20. PubMed ID: 21806945
[TBL] [Abstract][Full Text] [Related]
13. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.
Peyrin-Biroulet L; Khosrotehrani K; Carrat F; Bouvier AM; Chevaux JB; Simon T; Carbonnel F; Colombel JF; Dupas JL; Godeberge P; Hugot JP; Lémann M; Nahon S; Sabaté JM; Tucat G; Beaugerie L;
Gastroenterology; 2011 Nov; 141(5):1621-28.e1-5. PubMed ID: 21708105
[TBL] [Abstract][Full Text] [Related]
14. Evidence that Gsta4 modifies susceptibility to skin tumor development in mice and humans.
Abel EL; Angel JM; Riggs PK; Langfield L; Lo HH; Person MD; Awasthi YC; Wang LE; Strom SS; Wei Q; DiGiovanni J
J Natl Cancer Inst; 2010 Nov; 102(21):1663-75. PubMed ID: 20966433
[TBL] [Abstract][Full Text] [Related]
15. Promoter methylation of the
Klasić M; Markulin D; Vojta A; Samaržija I; Biruš I; Dobrinić P; Ventham NT; Trbojević-Akmačić I; Šimurina M; Štambuk J; Razdorov G; Kennedy NA; Satsangi J; Dias AM; Pinho S; Annese V; Latiano A; D'Inca R; ; Lauc G; Zoldoš V
Clin Epigenetics; 2018; 10():75. PubMed ID: 29991969
[TBL] [Abstract][Full Text] [Related]
16. Risk of skin cancer in patients with diabetes mellitus: A nationwide retrospective cohort study in Taiwan.
Tseng HW; Shiue YL; Tsai KW; Huang WC; Tang PL; Lam HC
Medicine (Baltimore); 2016 Jun; 95(26):e4070. PubMed ID: 27368048
[TBL] [Abstract][Full Text] [Related]
17. Increased non-melanoma skin cancer risk in young patients with inflammatory bowel disease on immunomodulatory therapy: a retrospective single-centre cohort study.
Clowry J; Sheridan J; Healy R; Deady S; Keegan D; Byrne K; Cullen G; Mulcahy H; Comber H; Parnell AC; Doherty G; Lally A
J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):978-985. PubMed ID: 28045204
[TBL] [Abstract][Full Text] [Related]
18. Polygenic risk score of non-melanoma skin cancer predicts post-transplant skin cancer across multiple organ types.
Stapleton CP; Chang BL; Keating BJ; Conlon PJ; Cavalleri GL
Clin Transplant; 2020 Aug; 34(8):e13904. PubMed ID: 32400091
[TBL] [Abstract][Full Text] [Related]
19. Nonmelanoma Skin Cancer Frequency and Risk Factors in Australian Heart and Lung Transplant Recipients.
De Rosa N; Paddon VL; Liu Z; Glanville AR; Parsi K
JAMA Dermatol; 2019 Jun; 155(6):716-719. PubMed ID: 30865218
[TBL] [Abstract][Full Text] [Related]
20. Genetic variant association of PTPN22, CTLA4, IL2RA, as well as HLA frequencies in susceptibility to alopecia areata.
Moravvej H; Tabatabaei-Panah PS; Abgoon R; Khaksar L; Sokhandan M; Tarshaei S; Ghaderian SMH; Ludwig RJ; Akbarzadeh R
Immunol Invest; 2018 Oct; 47(7):666-679. PubMed ID: 29979892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
